Amal achieves proof of concept

Please login or
register
29.06.2015

Amal Therapeutics published a port of its research finding in “Cancer Research”, the most frequently cited cancer journal in the world. The results are demonstrating the proof of concept and are showing the strength of Amal’s platform.

Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, was published on-line on the Cancer Research website. The article shows that vaccines tested are able to significantly prolonged survival in three robust tumor models.

The results published are demonstrating the proof of concept and showing the strength of Amal’s platform for the development of potent, safe and efficacious cancer vaccines”, said Dr. Derouazi, CEO of Amal Therapeutics. “Having the outcome of our work published in Cancer Research is a great success and a value recognition of the scientific approach taken since Amal’s incorporation in 2012”, added Dr. Derouazi.

About Amal Therapeutics
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

0Comments

More news about

Amal Therapeutics SA

Company profiles on startup.ch

Amal Therapeutics SA

rss